8-K: Celcuity Secures $500M Upsized Loan Facility, Extends Maturity

Celcuity Inc. announced an amendment to its senior secured credit facility, increasing total capital availability to $500 million and extending the maturity date to November 2029.

Summary

• The senior secured credit facility was amended, increasing the total size to $500 million, comprising $350 million in committed capital and an additional $150 million available at the mutual discretion of Celcuity and its lenders.
• An initial $30 million Term D Loan was immediately disbursed, bringing the total outstanding term loan to $130 million.
• The Term D Milestone was achieved prior to the amendment, based on positive data from the VIKTORIA-1 trial's wild-type patient population and compliance with performance covenants.
• The Term E Loan commitment was increased from $50 million to $100 million, available upon U.S. Food and Drug Administration (FDA) approval of gedatolisib in second-line wild-type advanced breast cancer patients post-CDK4/6 inhibitor therapy.
• Three new Term F Loans, each for $40 million (total $120 million), were added, contingent on achieving specific trailing three-month product revenue thresholds.
• The prior $45 million Term F Loan was replaced with a new $150 million Term G Loan, which remains available at the lenders' sole discretion.
• The maturity date for the term loans was extended to November 1, 2029.
• The interest-only period was extended by 14 months, with a potential additional 7-month extension available upon FDA approval.
• Celcuity issued warrants to purchase an aggregate of 50,537 shares of common stock to the lenders and their affiliates, exercisable at $14.84 per share through September 9, 2035.
• An amendment fee of $50,000 was paid to the lenders.
• Non-utilization fees of 3.0% apply to unfunded Term E and Term F commitments if not drawn and no timely notice of reduction is provided.

Sentiment

Score: 8

Explanation: The filing indicates a strong positive development for Celcuity, securing substantial financing and extending debt terms following positive clinical trial data. This significantly de-risks their near-term funding needs for drug development and commercialization. The issuance of warrants and non-utilization fees are minor considerations compared to the overall capital access and flexibility gained.

Positives

• Increased capital availability to $500 million, with $350 million committed, providing significant financial flexibility for ongoing operations and strategic initiatives.
• Immediate disbursement of $30 million Term D Loan, bringing total outstanding to $130 million, bolstering current liquidity.
• Achievement of the Term D Milestone, indicating positive topline clinical trial data for gedatolisib's VIKTORIA-1 trial (wild-type cohort) and compliance with performance covenants.
• Extension of the term loan maturity date to November 1, 2029, providing a longer repayment horizon.
• Extension of the interest-only period by 14 months, with a potential additional 7-month extension upon FDA approval, improving near-term cash flow management.
• Upsized Term E Loan to $100 million and added $120 million in new Term F Loans, providing substantial future funding contingent on key milestones (FDA approval, revenue thresholds).
• Strengthens the company's ability to support New Drug Application (NDA) submission, commercial launch preparations for gedatolisib, and other strategic initiatives.

Negatives

• Issuance of warrants for 50,537 shares of common stock to lenders, representing potential future dilution for existing shareholders.
• Non-utilization fees of 3.0% apply to unfunded Term E and Term F commitments if milestones are met but funds are not drawn and timely notice of reduction is not provided, creating a financial penalty.
• The $150 million Term G Loan remains at the lenders' sole discretion, not guaranteed committed capital.
• An amendment fee of $50,000 was paid to the lenders.

Risks

• Failure to achieve the Term E Milestone (FDA approval of gedatolisib) or Term F Milestones (product revenue thresholds) could limit access to significant portions of the facility ($100 million Term E, $120 million Term F).
• Potential for dilution from the exercise of 50,537 warrants issued to lenders.
• Risk of delisting from NASDAQ Capital Market if the company fails to comply with continued listing standards.
• Regulatory actions by the FDA, DOJ, or other governmental authorities, including warning letters, recalls, or enforcement actions, could trigger an Event of Default or materially impact the business.
• Failure to maintain the Minimum Liquidity Percentage (30% of outstanding Term Loans, decreasing to 25% upon Term E Milestone) could lead to an Event of Default.
• Failure to meet the Performance Covenant (Section 6.12) once triggered, unless waived by market capitalization or cash balance thresholds, could result in an Event of Default.
• A Material Adverse Change in the business, operations, or financial condition of Celcuity or any subsidiary could trigger an Event of Default.
• Default under other agreements with third parties resulting in acceleration of Indebtedness in excess of $250,000 or a Material Adverse Change.
• Judgments, orders, or decrees for the payment of money exceeding $250,000 (not paid or covered by independent third-party insurance) remaining unsatisfied for a period of ten days.
• Insolvency proceedings initiated by or against Celcuity or any of its subsidiaries.

Future Outlook

Celcuity anticipates using the enhanced financial flexibility and additional funding to support the rolling submission of its New Drug Application (NDA) for gedatolisib to the FDA via the RTOR program, prepare for the commercial launch of gedatolisib, and pursue other strategic initiatives. Future access to significant loan tranches is contingent on achieving FDA approval for gedatolisib in second-line wild-type advanced breast cancer patients and specific product revenue milestones.

Management Comments

• The amendment significantly enhances Celcuity's financial flexibility and access to capital following the positive topline data from the PIK3CA wild-type cohort of the pivotal VIKTORIA-1 Phase 3 clinical study.
• The upsized facility strengthens Celcuity's ability to manage its capital structure efficiently while providing additional funding to support the rolling submission to FDA of its New Drug Application (NDA) via FDA's RTOR program, commercial launch preparations for gedatolisib, and other strategic initiatives.

Industry Context

This financing amendment reflects a common strategy in the clinical-stage biotechnology sector, where companies secure debt facilities to fund late-stage clinical development and commercialization efforts, particularly after achieving positive clinical trial milestones. The structure, with tranches tied to FDA approval and revenue milestones, aligns with industry practices for de-risking lender exposure while providing growth capital. The focus on gedatolisib for advanced breast cancer and prostate cancer positions Celcuity in competitive oncology markets, where successful drug development and regulatory approval are critical for valuation and market entry.

Corporate Governance

Related Party Transactions

• Issuance of warrants to purchase 50,537 shares of common stock to Innovatus, Oxford, and certain of their affiliates, who are also the lenders in the credit facility.
• Innovatus has a right to convert up to 20% of the outstanding principal amount of the Term A Loan into shares of Common Stock of Borrower at a price of $10.00 per share until May 9, 2026.

Stakeholder Impact

• Shareholders: Potential future dilution from the exercise of 50,537 warrants issued to lenders. However, the increased capital availability and extended debt maturity could support long-term growth and reduce immediate financing risks, potentially benefiting share value.
• Lenders (Innovatus, Oxford, etc.): Gained warrants for potential equity upside, received an amendment fee, and secured a larger, extended loan facility with tranches tied to key milestones, enhancing their security and potential returns.
• Employees: Continued funding supports ongoing clinical trials and commercialization efforts, providing stability and potential growth opportunities.
• Patients: Continued development and potential commercialization of gedatolisib could offer new treatment options for advanced breast cancer and prostate cancer.

Next Steps

• Rolling submission of New Drug Application (NDA) for gedatolisib to the FDA via the RTOR program.
• Commercial launch preparations for gedatolisib.
• Continued enrollment for the PIK3CA mutant cohort of the VIKTORIA-1 Phase 3 clinical study.
• Ongoing Phase 1/2 clinical trial (CELC-G-201) for gedatolisib in metastatic castration resistant prostate cancer.
• Continued enrollment for the VIKTORIA-2 Phase 3 clinical trial for gedatolisib as first-line treatment for HR+/HER2ABC.
• Potential drawing of Term E Loan upon FDA approval of gedatolisib.
• Potential drawing of Term F Loans upon achievement of product revenue thresholds.
• Compliance with post-closing conditions for the loan amendment, including delivering insurance certificates and endorsements, amended landlord consents, bailee waivers, and control agreements for collateral accounts.

Key Dates

Recommendation

The significant upsize and extension of the senior secured credit facility, coupled with the achievement of the Term D Milestone (positive clinical data for gedatolisib), substantially de-risks Celcuity's financial position and provides a clear runway for advancing its lead therapeutic candidate towards NDA submission and commercialization. The structured tranches tied to FDA approval and revenue milestones demonstrate confidence from sophisticated lenders in the company's future prospects. While there is minor dilution from warrants, the overall enhancement in financial flexibility and the positive clinical progress outweigh this, making the stock an attractive 'buy' for investors looking for growth in the oncology biotech space.

Keywords

Celcuity Inc., CELC, Loan Agreement, Credit Facility, Debt Financing, Biotechnology, Oncology, Gedatolisib, FDA Approval, Clinical Trials, VIKTORIA-1, Term Loan, Warrants, Financial Flexibility, Capital Raise, Oxford Finance, Innovatus Capital Partners, SEC Filing, 8-K